MarketCap
Facebook
X
Telegram
TELA Bio Net Income | TELA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income TELA Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -38.8 M | -37.8 M | -46.7 M | -44.3 M | -33.3 M | -28.8 M | -22.4 M | -21.1 M | -21.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.1 M | -46.7 M | -32.7 M |
Quarterly Net Income TELA Bio
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.92 M | -12.3 M | - | -8.6 M | -9.92 M | -11.3 M | - | -10.4 M | -12.6 M | -5.66 M | - | -11 M | -10.8 M | -12 M | - | -10.7 M | -12.7 M | -10.9 M | - | -8.27 M | -8.26 M | -8.14 M | - | -7.7 M | -6.08 M | -7.22 M | - | -4.67 M | -5.26 M | -5.97 M | - | -2.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.81 M | -12.7 M | -8.88 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GBS
GBS
|
-12.4 M | - | -0.57 % | $ 7.12 M |  USA |
 |
Second Sight Medical Products
EYES
|
26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Inogen
INGN
|
22.7 M | $ 5.45 | 1.11 % | $ 145 M | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 125.5 | 0.15 % | $ 4.36 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 22.59 | 1.17 % | $ 530 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 81.2 | 2.79 % | $ 4.43 B |  Britain |
 |
Cognyte Software Ltd.
CGNT
|
-638 K | $ 8.48 | 0.71 % | $ 618 M |  Israel |
|
LENSAR
LNSR
|
-34.3 M | $ 8.25 | 0.06 % | $ 98.7 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 14.05 | 0.67 % | $ 398 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.4 | 1.42 % | $ 58.6 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Nano-X Imaging Ltd.
NNOX
|
-75 M | $ 0.71 | 1.3 % | $ 46 M | Israel |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
PAVmed
PAVM
|
-3.77 M | $ 5.09 | 0.19 % | $ 3.41 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 150.58 | 1.65 % | $ 10.6 B | USA |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 2.58 | 3.98 % | $ 110 M | USA |
 |
AVITA Medical
RCEL
|
-48.6 M | $ 10.94 | 1.67 % | $ 305 M |  Australia |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.35 | 0.94 % | $ 21.8 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.54 | 1.32 % | $ 4.27 M | USA |
 |
SmileDirectClub
SDC
|
-86.4 M | - | -53.45 % | $ 9.71 M | USA |
 |
Sientra
SIEN
|
-22 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-55.7 M | - | - | $ 1.07 B | USA |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |
 |
Surgalign Holdings
SRGA
|
-54.6 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
147 M | - | - | $ 12.3 B | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | USA |